Continuing treatment not beneficial after five years of bisphosphonates

For women who have received five years of bisphosphonate therapy, hip fracture risk does not differ with continuing treatment for an additional five years versus discontinuing treatment, according to a study published online Dec. 7 in JAMA Network Open.